p. 1325–1332; Submitted by Suelen Reis (suziy.ellen@gmail.com) on 2014-04-07T13:34:29Z No. of bitstreams: 1 10.6061clinics2013(10)06.pdf: 496812 bytes, checksum: d927f46be1656035b2fde06f6361dd1c (MD5); Approved for entry into archive by Rodrigo Meirelles (rodrigomei@ufba.br) on 2014-09-09T14:55:05Z (GMT) No. of bitstreams: 1 10.6061clinics2013(10)06.pdf: 496812 bytes, checksum: d927f46be1656035b2fde06f6361dd1c ...
Texto completo: acesso restrito. p. 476–486; Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2014-08-19T13:40:07Z No. of bitstreams: 1 Lourianne N. Cavalcante.pdf: 230836 bytes, checksum: 6a5af776161023563ae193168f44a8c2 (MD5); Approved for entry into archive by Delba Rosa (delba@ufba.br) on 2014-08-22T14:49:14Z (GMT) No. of bitstreams: 1 Lourianne N. Cavalcante.pdf: 230836 bytes, checksum: 6a5af7761610...
OBJECTIVES: Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association with IL28 might increase the power to predict sustained virologic response. Our aims were to evaluate the association between myxovirus resistance protein, osteopontin and suppressor of cytokine signaling 3...